

KO 63116

DEC - 5 20116

Section III - 510(k) Summary of Safety and Effectiveness

Submitter:

Sybron Dental Specialties, Inc. 100 Bayview Circle, Suite 6000 Newport Beach, California 92660 (949) 255-8766 - Phone (949) 255-8763 - Facsimile Colleen Boswell - Contact Person

Date Summary Prepared: October 2006

Device Name:

- Trade Name Demetron A.2
- Common Name L.E.D. Curing Light
- Classification Name Ultraviolet activator for polymerization, per 21 CFR § 872.6070

<u>Devices for Which Substantial Equivalence is Claimed:</u>

• Kerr Corporation, Demetron I.D.S.

Device Description:

The *Demetron A.2* is a Light Emitting Diode (LED) visible light curing unit used for the polymerization of light-cure materials. The *Demetron A.2* consists of an LED curing handpiece and wall plug-in transformer. The plastic molded handpiece will contain an LED light "engine", a cooling fan and a printed circuit board. A digital circuit and microprocessor will be utilized to control two (2) different curing modes. Each mode specifies LED curing output, fan, and audible beep timing. A pushbutton "trigger" switch will be used to select the curing mode and activate the LED curing output.

Intended Use of the Device:

The intended use of *Demetron A.2* is for the polymerization of visible light-cure materials by dental professionals.

Substantial Equivalence:

Demetron A.2 is substantially equivalent to other legally marketed devices in the United States. Demetron A.2 functions in a manner similar to and is intended for the same use as the Demetron I.D.S. designed by Kerr Corporation.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Colleen Boswell Director, Regulatory Affairs Sybron Dental Specialties, Incorporated 100 Bayview Circle, Suite 6000 Newport Beach, California 92660 DEC - 5 2006

Re: K063116

Trade/Device Name: Demetron A.2 Regulation Number: 21 CFR 872.6070

Regulation Name: Ultraviolet Activator for Polymerization

Regulatory Class: II Product Code: EBZ Dated: October 11, 2006 Received: October 12, 2006

Dear Ms. Boswell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Chiu S. Lin, PhD

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation

suite y Michaelomo.

Center for Devices and Radiological Health

Enclosure

Indications for Use

| | mulcations i | or use |
|--|----------------------|--|
| 510(k) Number (if known): | K06316 | |
| Device Name: Demetron A.2 | | |
| Indications for Use: | | |
| The <i>Demetron A.2</i> is a L.E.D. cure materials by dental profe | | unit intended for polymerization of light |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Prescription Use (Part 21 CFR 801 Subpart D) | AND/OR | Over-The-Counter Use(21 CFR 807 Subpart C) |
| (PLEASE DO NOT WRITE I IF NEEDED) | BELOW THIS LINE | - CONTINUE ON ANOTHER PAGE |
| Concurrence of | of CDRH, Office of I | Device Evaluation (ODE) |

Sign-Off)
sion of Anesthesiology, General Hospital,
secon Control, Dental Devices

12 Marchan (COG3)) 1

Page 1 of <u>1</u>